scholarly journals Depressive and Anxiety Disorders in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Ru Bai ◽  
Shuang Liu ◽  
Yueyin Zhao ◽  
Yuqi Cheng ◽  
Shu Li ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Anxiety Disorders ◽  
Disease Activity ◽  
Emotional Disorders ◽  
Lupus Erythematosus ◽  
Rating Scale ◽  
Depression And Anxiety ◽  
Systemic Lupus ◽  
Prevalence Of Depression ◽  
Neuropsychiatric Manifestations

Depressive and anxiety disorders are frequently observed in patients with Systemic Lupus Erythematosus (SLE). However, the underlying mechanisms are still unknown. We conducted this survey to understand the prevalence of depression and anxiety in SLE patients without major neuropsychiatric manifestations (non-NPSLE) and to explore the relationship between emotional disorders, symptoms, autoantibodies, disease activity, and treatments in SLE. 176 SLE patients were included, and SLE disease activity index (SLEDAI), Hamilton Depression Rating Scale (HAMD), and Hamilton Anxiety Rating Scale (HAMA) were recorded to evaluate their disease activity and emotional status. We found that depressive and anxiety disorders were common among SLE patients: 121 (68.8%) patients were in depression status while 14 (8.0%) patients could be diagnosed with depression. Accordingly, 101 (57.4%) were in anxiety status and 21 (11.9%) could be diagnosed with anxiety. Depression was associated with disease activity, and anxiety was associated with anti-P0 antibody, while both of them were associated with proteinuria. HAMA and HAMD scores were in strong positive correlation and they were independent risk factors of each other. We concluded that the high prevalence of depression and anxiety and the association between depression and SLE disease activity might reveal the covert damage of central nervous system in SLE. The role of anti-P0 antibody in SLE patients with emotional disorders warrants more researches.

Reliability of Visual Analog Scale and Numeric Rating Scale for the Assessment of Disease Activity in Systemic Lupus Erythematosus

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Claudia Elera-Fitzcarrald ◽  
Karen Vega ◽  
Rocío V. Gamboa-Cárdenas ◽  
Katiuska Zúñiga ◽  
Francisco Zevallos ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Visual Analog Scale ◽  
Lupus Erythematosus ◽  
Rating Scale ◽  
Numeric Rating Scale ◽  
Systemic Lupus ◽  
Analog Scale ◽  
Numeric Rating ◽  
Assessment Of Disease Activity

scholarly journals Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Shuang Liu ◽  
Yuqi Cheng ◽  
Yueyin Zhao ◽  
Aiyun Lai ◽  
Zhaoping Lv ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Structural Changes ◽  
Activity Index ◽  
Disease Activity Index ◽  
Hippocampal Damage ◽  
Hippocampal Atrophy ◽  
Systemic Lupus ◽  
Neuropsychiatric Manifestations

This study was conducted to explore hippocampal structural changes and their possible associations with clinical characteristics, emotional status, and treatment regimens in patients with systemic lupus erythematosus (SLE) without major neuropsychiatric manifestations (non-NPSLE). Eighty-five non-NPSLE patients with normal conventional magnetic resonance imaging (MRI) and seventy-seven matched healthy control (HC) subjects were recruited. All participants underwent the standard high-resolution volumetric MRI. The bilateral hippocampal volume (HIPV) and hippocampal density (HIPD) were calculated, respectively, for each participant. We found that the bilateral HIPV and HIPD of the SLE patient group were significantly less than those of the HC group. The bilateral HIPV of female patients were significantly less than those of male patients. The SLE disease activity index (SLEDAI) was negatively correlated with the bilateral HIPV and the right HIPD. Urine protein quantity was negatively correlated with the bilateral HIPV and HIPD. Hydroxychloroquine (HCQ) showed a protective effect on right HIPV. In conclusion, we found that the early hippocampal atrophy could occur before obvious neuropsychiatric manifestations and might be associated with SLE disease activity and organ damages. Early detection and intervention of hippocampal damage might prevent the progression to NPSLE. More studies are needed to fully understand the underlying mechanisms of hippocampal atrophy in SLE.

scholarly journals Shared pathological mechanisms of systemic lupus erythematosus and affective disorders

2021 ◽  
Vol 13 (2) ◽  
pp. 5-14
Author(s):  
Grigory V. Rukavishnikov ◽  
Anna A. Smirnova ◽  
Nikolay G. Neznanov ◽  
Vadim I. Mazurov ◽  
Galina E. Mazo
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Affective Disorders ◽  
Psychiatric Symptoms ◽  
Clinical Manifestations ◽  
Depression And Anxiety ◽  
Systemic Lupus ◽  
High Prevalence ◽  
Neuropsychiatric Manifestations ◽  
Therapeutic Measures

The high prevalence and variability of neurological and psychiatric symptoms in systemic lupus erythematosus has become the basis for emphasizing the special neuropsychiatric form of the disorder. Affective disorders (pathological changes in mood and anxiety) are the second most common neuropsychiatric manifestations in patients with systemic lupus erythematosus. However, the current nomenclature primarily focuses on the general clinical manifestations of affective disorders in neuropsychiatric form systemic lupus erythematosus, without evaluating the problems of their etiopathogenesis. Thereby, the aim of this review is the integration of information on the pathological mechanisms of depression and anxiety in patients with systemic lupus erythematosus. The available data on the biological aspects of the anxiety and depression in systemic lupus erythematosus indicate that the complex pathological models may be the best approach for studying, diagnosing, and treating comorbid pathology. The latter can be based on expanding the existing clinical categories, supplementing them with data on pathological mechanisms specific to particular sub-cohorts of patients. Such an approach can provide the specific and most effective preventive, diagnostic and therapeutic measures for each category of patients.

Sign in / Sign up

Export Citation Format

Share Document